30 results
8-K
EX-1.1
ARCT
Arcturus Therapeutics Holdings Inc
29 Jul 20
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
6:02am
Prospectus.
The “Pricing Disclosure Package” shall mean (i) the Base Prospectus, (ii) the Preliminary Prospectus used most recently prior … Prospectus”), that the parties hereto shall hereafter expressly agree in writing to treat as part of the Pricing Disclosure Package and (v) the pricing
8-K
EX-1.1
ARCT
Arcturus Therapeutics Holdings Inc
17 Apr 20
Entry into a Material Definitive Agreement
6:06am
, together with the Base Prospectus.
The “Pricing Disclosure Package” shall mean (i) the Base Prospectus, (ii) the Preliminary Prospectus used most … Package and (v) the pricing information identified in Schedule III hereto.
As used herein, “Applicable Time” is 8:00 a.m. (New York City time) on April
8-K
EX-1.1
ARCT
Arcturus Therapeutics Holdings Inc
8 Dec 20
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
9:01am
, together with the Base Prospectus.
The “Pricing Disclosure Package” shall mean (i) the Base Prospectus, (ii) the Preliminary Prospectus used most … Package and (v) the pricing information identified in Schedule III hereto.
As used herein, “Applicable Time” is 8:00 p.m. (New York City time) on December
10-K
2019 FY
EX-10.24
ARCT
Arcturus Therapeutics Holdings Inc
16 Mar 20
Annual report
11:09am
is a standard component in the personnel's salary package;
iv.It is paid out during the Qualifying Period (regardless of the period for which the AWS … per calendar year and is
qualifying only if –
i. It is a standard component in the personnel’s salary package;
ii. It is paid out during
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
20 Apr 22
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
5:24pm
in parallel with this filing. This additional efficacy data complements the data package under review by the Vietnam Ministry of Health for potential Emergency
8-K
EX-99.1
hddt9h2 qte08
9 May 22
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
4:20pm
8-K
EX-10.2
szsrfe32zi
20 Jun 19
License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
6:06am
DEFR14A
ptimtkyb
12 May 22
Revised proxy
5:00pm